DHODH Inhibition Suppresses MYC and Inhibits the Growth of Medulloblastoma in a Novel In Vivo Zebrafish Model
Our findings indicate that DHODH is a promising therapeutic target in group 3 MBs. Furthermore, BRQ shows potential for clinical application, effectively reducing tumour growth and <i>MYC</i> expression in vitro and in vivo. Moreover, our newly established zebrafish xenograft model offers a promising avenue for rapid in vivo drug testing for use in MB.
Authors
- Ιωάννα Τσέα (ORCID: https://orcid.org/0000-0002-6879-5490)
- Ninib Baryawno (ORCID: https://orcid.org/0000-0001-6054-4163)
- Thale Kristin Olsen (ORCID: https://orcid.org/0000-0003-4655-7384)
- Cecilia Dyberg
- Conny Tümmler (ORCID: https://orcid.org/0000-0002-5530-4752)
- Panagiotis Alkinoos Polychronopoulos (ORCID: https://orcid.org/0009-0004-3144-5712)
- D. Sykes (ORCID: https://orcid.org/0000-0002-7578-890X)
Institutions
- Uppsala University (SE)
- Karolinska Institutet (SE)
- Massachusetts General Hospital (US)
Publication Details
- Journal
- Cancers
- Published
- 2024-12-13
- DOI
- https://doi.org/10.3390/cancers16244162
- Citations
- 5
- Primary Topic
- Epigenetics and DNA Methylation
- Type
- article
- Field-Weighted Citation Impact
- 1.17
Funders
- American Society of Hematology
- Barncancerfonden